raloxifene hydrochloride has been researched along with Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Mutoh, M; Wakabayashi, K | 1 |
| Adhikari, N; Bhattacharjee, M; Gupta, D; Pamnani, S; Panda, A; Rizvi, Z; Shehzad, S; Sijwali, PS; Sudhakar, R | 1 |
| Bhatia, S; Kamboj, S; Rana, V; Sethi, S; Singh, RS | 1 |
| Jain, SK; Kaur, R; Kaur, S; Kumar, M; Narendra, G; Raju, B; Sapra, B; Silakari, O; Singh, PK; Thakur, S; Tung, GK; Verma, H | 1 |
| Dorn, J; Drecoll, E; Frejno, M; Heinzlmeir, S; Helm, D; Hogrebe, A; Kleigrewe, K; Kuster, B; Kvasnicka, HM; Meng, C; Mergner, J; Oellerich, T; Ruprecht, B; Samaras, P; Scheich, S; Serve, H; Weichert, W; Wilhelm, M; Zecha, J | 1 |
| Mahanta, AK; Maiti, P; Rana, D; Senapati, S; Shukla, R; Tripathi, YB | 1 |
| Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC | 1 |
| Grabowski, HG; Moe, JL | 1 |
| Peng, J; Xiahou, G; Yang, M; Yang, Z; Zhang, J | 1 |
| Frye, CA; Walf, AA | 1 |
| Alves, NJ; Berkowitz, J; Bilgicer, B; Chaudhuri, P; Chin, KT; Dinulescu, DM; Handlogten, MW; Mashelkar, RA; Muto, KW; Paraskar, AS; Sengupta, S; Soni, S | 1 |
| Akamatsu, K; Kurose, H; Kusakabe, M; Li, ZL; Morimoto, J; Ohmichi, M; Otsuki, Y; Shibata, E; Shibata, MA | 1 |
| Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 1 |
| Christopoulos, S; Rivera, JA; Small, D; Trifiro, M | 1 |
| Brandi, ML; Picariello, L; Tonelli, F | 1 |
| Lippman, SM | 1 |
| Szabo, E | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Ziegler, J | 1 |
| Gescher, AJ; O'Byrne, KJ; Sharma, RA; Steward, WP | 1 |
| Dominguez, JE; Shortle, B; Warren, MP | 1 |
7 review(s) available for raloxifene hydrochloride and Neoplasms
| Article | Year |
|---|---|
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome | 2008 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropathies; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasms; Nitriles; Radiography, Thoracic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; Uterine Neoplasms | 2004 |
Selective oestrogen receptor modulators in desmoid tumours.
Topics: Animals; Fibromatosis, Aggressive; Humans; Neoplasms; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2004 |
Selecting targets for cancer prevention: where do we go from here?
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2006 |
[Osteoporosis in cancer survivors].
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2007 |
Familiar drugs may prevent cancer.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticarcinogenic Agents; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Female; Folic Acid; Humans; Male; Neoplasms; Pyrazoles; Raloxifene Hydrochloride; Sulfonamides; Tamoxifen; Vitamin A | 2001 |
Use of alternative therapies in menopause.
Topics: Cardiovascular Diseases; Estrogens; Female; Humans; Hypercholesterolemia; Isoflavones; Lignans; Menopause; Middle Aged; Neoplasms; Osteoporosis, Postmenopausal; Phytotherapy; Plant Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
16 other study(ies) available for raloxifene hydrochloride and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
[Recent Trends in Chemoprevention of Cancer].
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Neoplasms; Raloxifene Hydrochloride; Tamoxifen | 2021 |
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.
Topics: Animals; Antimalarials; Female; Heme; Hemeproteins; Hemoglobins; Humans; Indoles; Malaria; Malaria, Falciparum; Male; Mice; Neoplasms; Osteoporosis, Postmenopausal; Plasmodium falciparum; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2022 |
Assessing the viability of carbamoylethyl pullulan-g-stearic acid based smart polymeric micelles for tumor targeting of raloxifene.
Topics: Glucans; Humans; Micelles; Neoplasms; Polymers; Raloxifene Hydrochloride; Stearic Acids; Tissue Distribution | 2021 |
Raloxifene and bazedoxifene as selective ALDH1A1 inhibitors to ameliorate cyclophosphamide resistance: A drug repurposing approach.
Topics: Aldehyde Dehydrogenase 1 Family; Aldehyde Dehydrogenase, Mitochondrial; Cyclophosphamide; Drug Repositioning; Humans; Molecular Docking Simulation; Neoplasms; Raloxifene Hydrochloride; Retinal Dehydrogenase | 2023 |
Proteome activity landscapes of tumor cell lines determine drug responses.
Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Computer Simulation; Cytarabine; Drug Development; Genomics; Humans; Leukemia, Myeloid, Acute; Neoplasms; Proteome; Proteomics; Raloxifene Hydrochloride; Receptors, Progesterone; Signal Transduction | 2020 |
Engineered Cellular Uptake and Controlled Drug Delivery Using Two Dimensional Nanoparticle and Polymer for Cancer Treatment.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biological Availability; Chemical Engineering; Delayed-Action Preparations; Diffusion; Drug Delivery Systems; Female; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxides; Inhibitory Concentration 50; Liver; Mice; Nanoparticles; Neoplasms; Pharmaceutical Vehicles; Polymers; Raloxifene Hydrochloride; Rats; X-Ray Diffraction; Zinc Compounds | 2018 |
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
Topics: Antineoplastic Agents; Biomedical Research; Chemoprevention; Drug Discovery; Drug Industry; Humans; Intellectual Property; Liability, Legal; Neoplasms; Orphan Drug Production; Patents as Topic; Raloxifene Hydrochloride | 2008 |
Targeted delivery of insulin-modified immunoliposomes in vivo.
Topics: Animals; Drug Delivery Systems; Insulin; Liposomes; Mice; Neoplasms; Raloxifene Hydrochloride; Tissue Distribution | 2009 |
Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anxiety; Behavior, Animal; Carcinogens; Cell Proliferation; Depression; Disease Models, Animal; Drug Interactions; Estradiol; Estrogens; Female; Maze Learning; Neoplasms; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Long-Evans; Regression Analysis; Sexual Behavior, Animal; Swimming; Time Factors; Uterus | 2010 |
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.
Topics: Animals; Carboplatin; Cisplatin; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Nanotechnology; Neoplasms; Platinum; Polyenes; Polymers; Raloxifene Hydrochloride; Structure-Activity Relationship; Tissue Distribution | 2010 |
Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Estrogen Receptor alpha; Female; Humans; Lymphatic Metastasis; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Factors | 2010 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Denmark; Diabetes Complications; Diphosphonates; Drug Therapy; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Neoplasms; Organometallic Compounds; Osteitis; Osteomyelitis; Osteoporosis; Parathyroid Hormone; Periostitis; Radiotherapy; Raloxifene Hydrochloride; Risk Factors; Sjogren's Syndrome; Strontium; Thiophenes | 2012 |
The dilemma and promise of cancer chemoprevention.
Topics: Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Humans; Neoplasms; Raloxifene Hydrochloride; Risk Factors | 2006 |
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene | 1996 |
Cancer. Genotyping treatments.
Topics: Estrogen Antagonists; Female; Genotype; Humans; Neoplasms; Raloxifene Hydrochloride; Signal Transduction; Tamoxifen | 2000 |